Opinion

Video

Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway

Author(s):

Adam M. Brufsky, MD, PhD,Erika P. Hamilton, MD

Key opinion leaders explore the mechanisms of resistance that can develop after endocrine therapy and CDK4/6 inhibitor treatment in HR+/HER2- locally advanced or metastatic breast cancer, emphasizing the uncertain etiology of resistance and current hypotheses, while also examining biomarkers that may predict resistance to CDK4/6 inhibitors and endocrine therapy.

Related Videos
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
1 expert in this video
1 expert in this video
David Rimm, MD, PhD
Vered Stearns, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
1 expert in this video
1 expert in this video
Related Content
Breast Cancer
November 27th 2024

Adjuvant Ribociclib Wins EU Approval for HR+/HER2– Early Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The OncFive: Top Oncology Articles for the Week of 11/17
November 23rd 2024

The OncFive: Top Oncology Articles for the Week of 11/17

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, Diana Hyland Chair for Breast Cancer, University Hospitals Seidman Cancer Center
November 20th 2024

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

Lubna Naaz Chaudhary, MD, MS, associate professor, medicine, Medical College of Wisconsin
November 19th 2024

Ongoing and Planned Research Build on Prior Advancements in ER+/HER2– Breast Cancer